首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Expression of Keap1 and Nrf2 in diffuse large B-cell lymphoma and its clinical significance
【2h】

Expression of Keap1 and Nrf2 in diffuse large B-cell lymphoma and its clinical significance

机译:Keap1和Nrf2在弥漫性大B细胞淋巴瘤中的表达及其临床意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study investigated the expression and clinical significance of kelch-like ECH-associated protein 1 (Keap1) and nuclear factor erythroid-2-related factor-2 (Nrf2) expression in diffuse large B-cell lymphoma (DLBCL). These proteins were detected by immunohistochemistry in 39 DLBCL cases and 17 cases of reactive lymph node hyperplasia, and their association with the clinicopathological features of DLBCL patients was analyzed. In DLBCL, the percentage of cells with positive staining for Keap1 and Nrf2 was 46.2 and 35.9%, respectively, which was significantly higher than that in reactive lymph node hyperplasia (17.7 and 5.9%, respectively). There was no correlation between Keap1 and Nrf2 expression according to a Spearman rank correlation analysis (r=0.272; P>0.05). Keap1 and Nrf2 expression was associated with the international prognostic index and Ann-Arbor clinical stage (P<0.05), and Keap1 and Nrf2 expression was higher in DLBCL patients with stage III–IV (68.4 and 52.6%, respectively) compared with in those with stage I–II (25.0 and 20.0%, respectively). The aberrant expression of Keap1 and Nrf2 in DLBCL suggests that these factors may have crucial roles in the development and progression of the disease, and may therefore be used as prognostic indicators.
机译:本研究调查了在弥漫性大B细胞淋巴瘤(DLBCL)中表达的kelch样ECH相关蛋白1(Keap1)和核因子erythroid-2相关因子2(Nrf2)的表达及其临床意义。通过免疫组织化学法在39例DLBCL患者和17例反应性淋巴结增生患者中检测了这些蛋白,并分析了它们与DLBCL患者临床病理特征的关系。在DLBCL中,Keap1和Nrf2呈阳性染色的细胞百分比分别为46.2和35.9%,显着高于反应性淋巴结增生(分别为17.7和5.9%)。根据Spearman秩相关分析,Keap1和Nrf2表达之间没有相关性(r = 0.272; P> 0.05)。 Keap1和Nrf2的表达与国际预后指数和Ann-Arbor临床分期相关(P <0.05),并且Keap1和Nrf2的表达在III–IV期的DLBCL患者中较高(分别为68.4和52.6%)。在I–II期(分别为25.0%和20.0%)。 DLBCL中Keap1和Nrf2的异常表达表明这些因素可能在疾病的发展和进程中起关键作用,因此可以用作预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号